Andere talen Blueprint Medicines Corporation

Aandelen

BPMC

US09627Y1091

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 02-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
107 ^USD	+12,66%		+17,93%	+16,00%

02/05	BLUEPRINT MEDICINES CORPORATION : Wedbush ontvangt een koopadvies	ZM
02/05	Aandelen Blueprint Medicines Stijgen Nadat Q1 naar nettowinst gaat, stijgt de omzet	MT

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Blueprint Medicines Shares Rise After Q1 Swings to Net Income, Revenue Rises	02/05
Earnings Flash (BPMC) BLUEPRINT MEDICINES CORPORATION Posts Q1 Revenue $96.1M, vs. Street Est of $81.4M	02/05
Blueprint Medicines: Q1 Earnings Snapshot	02/05
Blueprint Medicines Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	02/05
Blueprint Medicines Corporation Revises Revenue Guidance for the Full Year 2024	02/05
Blueprint Medicines to Report First Quarter 2024 Financial Results on Thursday, May 2, 2024	18/04
Blueprint Medicines to Host Webcast and Conference Call Highlighting Emerging Opportunities for Mast Cell-Targeted Therapeutics	11/04
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	04/04
Blueprint Medicines Insider Sold Shares Worth $2,188,265, According to a Recent SEC Filing	22/03
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	06/03
Blueprint Medicines Insider Sold Shares Worth $500,000, According to a Recent SEC Filing	01/03
Blueprint Medicines Highlights AYVAKIT Long-Term Efficacy and Safety Data and Advances in Mast Cell Disease Research at 2024 AAAAI Annual Meeting	26/02
Blueprint Medicines Says Ayvakit Data in Indolent Systemic Mastocytosis Show Long-Term Efficacy, Safety	23/02
Blueprint Medicines Highlights AYVAKIT (Avapritinib) Long-Term Efficacy and Safety Data and Advances in Mast Cell Disease Research at 2024 AAAAI Annual Meeting	23/02
Rigel Pharmaceuticals Acquires U.S. Rights to GAVRETO	22/02
Blueprint Medicines Q4 Loss Narrows, Revenue Rises; Shares Up	15/02
Blueprint Medicines Q4 Loss Narrows, Revenue Rises	15/02
Blueprint Medicines: Q4 Earnings Snapshot	15/02
Earnings Flash (BPMC) BLUEPRINT MEDICINES CORPORATION Reports Q4 Revenue $72M, vs. Street Est of $67.1M	15/02
Blueprint Medicines Corporation Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	15/02

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Blueprint Medicines Corporation

Aandelen

BPMC

US09627Y1091

Andere talen

Filters